Skip to main content

FDA Schedules ODAC Meeting on Ramucirumab/Erlotinib in Frontline EGFR+ NSCLC

*January 2020*

The FDA has scheduled an Oncologic Drugs Advisory Committee (ODAC) hearing for February 26, 2020, to discuss data supporting a supplemental biologics license application (sBLA) for intravenous ramucirumab (Cyramza) injection for use in combination with erlotinib (Tarceva) in the frontline treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors harbor EGFR Ex19del or Ex21 substitution mutations.1

Read more.